Status:
COMPLETED
Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression
Lead Sponsor:
Rutgers University
Collaborating Sponsors:
The Klingenstein Third Generation Foundation
Conditions:
Depressive Disorder
Anxiety Disorders
Eligibility:
All Genders
11-15 years
Phase:
NA
Brief Summary
Psychological therapies for depression have demonstrated efficacy, but outcomes are still unsatisfactory, especially in cases with high comorbidity. Depression and anxiety co-occur in up to 69-75% of ...
Detailed Description
Specific Aims and Hypotheses: This study will develop treatment materials for a transdiagnostic Group Behavioral Activation Therapy (GBAT). It will then conduct a double-gated screening of middle-sch...
Eligibility Criteria
Inclusion
- clinical (ADIS CSR ≥ 4) or subclinical (ADIS CSR = 2-3) principal diagnosis of either a DSM-IV-TR unipolar depression disorder (Major Depressive Disorder (\[MDD\], Minor Depression \[MinD\], or Dysthymia \[Dys\]) or
- an anxiety disorder (Generalized Anxiety Disorder \[GAD\], Social Phobia \[SOP\], Separation Anxiety \[SAD\]).
Exclusion
- any principal diagnosis other than anxiety or depression or parent report of mental retardation,
- pervasive developmental disorder,
- schizophrenia, or
- bipolar disorder, or
- report of past-year hospitalization for a suicide attempt. Concurrent use of antidepressant or anxiolytic medications was permitted as long as dosage was stable for at least four weeks and the family intended to maintain the dose.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
895 Patients enrolled
Trial Details
Trial ID
NCT01829100
Start Date
September 1 2009
End Date
June 1 2012
Last Update
October 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rutgers University
Piscataway, New Jersey, United States, 08854